Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 48Recruiting 19Terminated 14Unknown 10Active not recruiting 6Not yet recruiting 4Withdrawn 2Suspended 1Enrolling by invitation 1Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 20Thoracic 7Gastrointestinal 7Other solid neoplasm 3Other hematologic neoplasm 3Gynecologic 3Genitourinary 3CNS 3Other 2Head & Neck 2Breast 2Myeloid 1Lymphoid 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Hodgkin Disease 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Neoplasms × Endocrine × Clear all
NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

JS InnoPharm, LLC

Phase 1 Suspended
71 enrolled
DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡